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Dear Editor,
The del(5q) cytogenetic abnormality was ﬁrst described by Van
den Berghe et al. in 1974.1 The original manuscript described
ﬁve patients with a macrocytic anemia, dyserythropoiesis
with erythroid hypoplasia, normal to elevated platelet count,
hypolobulated megakaryocytes and an interstitial deletion
involving the long arm of chromosome 5. However, a dele-
tion of chromosome 5q in myelodysplastic syndrome (MDS)
does not necessarily equate to the clinically described 5q-
syndrome because, by deﬁnition, the 5q- syndrome is a dis-
tinct entity with the aforementioned clinical characteristics.2
As we  routinely evaluate patients with suspicion of MDS,
some unusual clinical situations have emerged in our clinical
practice.
In December 2013, a 65-year-old asymptomatic woman
was referred to us to investigate isolated leukopenia. The
physical exam was normal. The complete blood count
showed mild leukopenia (white blood cells 2.65 × 109/L –
neutrophils 36%, eosinophils 8%, basophils 0%, lymphocytes
48% and monocytes 8%), hemoglobin 12.3 g/dL (normal range
11.5–16.4 g/dL), mean corpuscular volume (MCV) 101.1 fL and
platelets 326 × 109/L. The patient was submitted to bone mar-
row (BM) aspiration and biopsy, as well as cytogenetic analysis
by G-banding.
The BM smear revealed a normocellular erythrocyte lin-
eage, characterized by the presence of dysplasia in 12%
of cells. The megakaryocytic lineage was hypercellular and
characterized by dysplasia in 28% of cells. The morpholog-
ically abnormal megakaryocytes exhibited a non-lobulated,
eccentric nucleus (Figure 1a). Occasionally, ‘dumbbell-type’
megakaryocytes were identiﬁed (Figure 1b).
The BM biopsy showed overall hypocellularity and
conﬁrmed the signiﬁcant dysmegakaryopoiesis. Dyserythro-
poiesis was characterized by megaloblastoid erythroblasts
(<10%). The granulocytic series showed no signiﬁcant abnor-
malities.Following the recommendations of the International Sys-
tem for Human Cytogenetic Nomenclature (ISCN 2013), the
cytogenetic analysis demonstrated a karyotype with a large isolated  del(5q)
interstitial deletion in the long arm of chromosome 5 (5q22) in
50% of 16 analyzed metaphases (46,XX,del(5)(q22)[8]/46,XX[8])
(Figure 1c).
The patient’s last medical consultation took place in June
2015 and she was asymptomatic. She continues to be followed
by her local hematologist.
In March 2015, the hemoglobin level dropped to 10.6 g/dL.
The last complete blood count dated June 2015 showed
white blood cells of 1.64 × 109/L – neutrophils 23.9%,
eosinophils 5.2%, basophils 0.5%, lymphocytes 61.6%,
monocytes 8.8% – hemoglobin 9.9 g/dL, MCV  109.1 fL,
and platelets 195 × 109/L. The median value and the
minimum–maximum value for hemoglobin, and neutrophil
and platelet counts during the period of the follow up were
11.5 g/dL (9.9–12 g/dL), 1.003 × 109/L (0.391–1.569 × 109/L) and
239 × 109/L (184–281 × 109/L), respectively.
Myelodysplastic syndromes are a group of clonal
hematopoietic disorders with diverse clinical presentations.3
A subset of patients have an isolated deletion of chromosome
5q, known as 5q- syndrome, which is characterized by a
distinct set of features including severe macrocytic anemia,
normal or slightly decreased neutrophil count, normal or
elevated platelet count and, in bone marrow, the presence of
hypolobulated megakaryocytes.2
Our patient has a large 5q deletion (5q22), which includes
both commonly deleted regions, 5q31 and 5q32-33. One of
the genes lost by these deletions is the adenomatous polypo-
sis coli (APC) gene that may contribute to the pathogenesis of
del(5q) MDS due to increased beta-catenin activity.4 Another
important affected gene is the Ribosomal Protein S14 (RPS14)
gene, located in the 5q31-q33 locus. RPS14 haploinsufﬁciency
is associated with increased apoptosis of erythroid precursors
and ineffective erythropoiesis. However, contrary to expec-
tations, our patient had no anemia at diagnosis and, thus,
we suggest that additional molecular abnormalities arising
over time, such as somatic mutations in individual genes and
epigenetic alterations, may also contribute to the many  dif-
ferent clinical phenotypes of patients with del(5q). Each of
these abnormalities has the potential to alter blood counts,
the percentage of blast cells in the BM and overall survival.4
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Figure 1 – (a) Megakaryocyte with a non-lobulated nucleus. (b) A ‘dumbbell-type’ megakaryocyte. (c) Karyotype showing a
large terminal deletion of chromosome 5 – 46,XX,del(5)(q22).
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sOur patient presented with some BM abnormalities typ-
cally found in patients with the classical 5q- syndrome as,
or example, the almost pathognomonic non-lobulated and
dumbbell-type’ megakaryocytes. On the other hand, severe
ransfusion-dependent macrocytic anemia, which is a char-
cteristic mark of this syndrome, is absent. Thus, given the
linical and laboratory ﬁndings of this case, it was not possi-
le to unequivocally deﬁne between the diagnosis of classical
q- syndrome as described by Van den Berghe1 and MDS with
solated del(5q).
However, we  concluded that, at present, this differential
iagnosis is not necessary in the clinical practice. This is
ecause, as demonstrated by recent evidence,5 therapy with
he orally active thalidomide analog, lenalidomide, can be
sed to treat patients with both conditions as it is indicated
or subjects with del(5q) and symptomatic anemia.
Finally, the effectiveness of lenalidomide in classical 5q-
yndrome and MDS  with isolated del(5q) supports the ﬁndingsin the World Health Organization (WHO) 2008 classiﬁcation,
that does not require speciﬁc differential diagnosis between
the entities. Nevertheless, it is still possible that each disease
may have different approaches in the future, as new molecu-
lar methods have contributed to better deﬁne the topographic
features of the genomic lesions involved in del(5q) over recent
years.
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